Other publication

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)

Authors: Mummery C.J., Börjesson-Hanson A., Blackburn D.J., Vijverberg E.G.B., De Deyn P.P., Ducharme S., Jonsson M., Schneider A., Rinne J.O., Ludolph A.C., Bodenschatz R., Kordasiewicz H., Swayze E.E., Fitzsimmons B., Mignon L., Moore K.M., Yun C., Baumann T., Li D., Norris D.A., Crean R., Graham D.L., Huang E., Ratti E., Bennett C.F., Junge C., Lane R.M.

Publisher: Nature Research

Publication year: 2024

Journal: Nature Medicine

Journal name in source: Nature Medicine

Article number: 304

Volume: 30

ISSN: 1078-8956

eISSN: 1546-170X

DOI: https://doi.org/10.1038/s41591-023-02639-3

Web address : https://www.nature.com/articles/s41591-023-02639-3

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/181983815